This Week: 'Home Run' in Prostate Ca, Cannabis Risks
(MedPage Today) -- Early docetaxel and anti-androgen therapy extended survival dramatically in metastatic prostate cancer, and NIDA officials published a review of marijuana's health risks that may have overstated the case. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 6, 2014 Category: Primary Care Source Type: news
ASCO: Drug Combo Highly Active in Metastatic CRPC
CHICAGO (MedPage Today) -- A small cohort of men with untreated metastatic castration-resistant prostate cancer had a PSA response rate of 86% with the combination of docetaxel and abiraterone, investigators reported here. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 4, 2014 Category: Geriatrics Source Type: news
New Approach May Boost Survival From Advanced Prostate Cancer
Adding generic docetaxel to standard hormonal treatment seems to have benefit, study shows (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - June 2, 2014 Category: Cancer & Oncology Source Type: news
ASCO: A 'Home Run' in Prostate Cancer Tx
CHICAGO (MedPage Today) -- Overall survival in metastatic prostate cancer improved by more than a year when patients received docetaxel at the start of androgen deprivation therapy, according to trial results that oncologists here called "unprecedented" and a "home run." (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 1, 2014 Category: Primary Care Source Type: news
Practice-Changing Results for Metastatic Prostate CancerPractice-Changing Results for Metastatic Prostate Cancer
For patients with metastatic hormone-sensitive prostate cancer, upfront chemotherapy with docetaxel, given at the same time as hormone therapy, prolongs survival, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
New Approach May Boost Survival From Advanced Prostate Cancer
Adding generic docetaxel to standard hormonal treatment seems to have benefit, study shows (Source: WebMD Health)
Source: WebMD Health - June 1, 2014 Category: Consumer Health News Source Type: news
New Approach May Boost Survival From Advanced Prostate Cancer
Adding generic docetaxel to standard hormonal treatment seems to have benefit, study shows (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 1, 2014 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Reproductive Medicine, News, Source Type: news
New Approach May Boost Survival from Advanced Prostate Cancer
Adding generic docetaxel to standard hormonal treatment seems to have benefit, study showsSource: HealthDay
Related MedlinePlus Pages: Cancer Chemotherapy, Prostate Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 1, 2014 Category: Consumer Health News Source Type: news
Radium-223 dichloride in prostate cancer: Major added benefit for certain patients
Radium-223 dichloride has been approved since November 2013 for men with advanced prostate cancer, in whom hormone blockade is no longer effective, and symptomatic bone metastases, but without visceral metastases. In an early benefit assessment, researchers examined whether this new drug offers an added benefit over the appropriate comparator therapy. No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal. Hence an added benefit is not proven for this comparison. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 3, 2014 Category: Science Source Type: news
Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer
When added to docetaxel in second-line therapy, the new agent improved survival in a subgroup of patients with adenocarcinoma histology. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC
Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - February 19, 2014 Category: Cancer & Oncology Source Type: news
Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC
Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease progression after first-line chemotherapy, phase III study results show. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - February 19, 2014 Category: Cancer & Oncology Source Type: news
No Survival Benefit in CRPC With New Anti-Androgen
SAN FRANCISCO (MedPage Today) -- An investigational anti-androgen failed to improve overall survival in a randomized trial of men with docetaxel-treated metastatic castration-resistant prostate cancer (CRPC). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 2, 2014 Category: Hematology Source Type: news
Starpharma to begin Phase I dendrimer-docetaxel study
Australia-based Starpharma has received necessary approvals to start a Phase I human clinical trial of its dendrimer-docetaxel (Taxotere) chemotherapeutic product, referred to as DEP-Docetaxel, for the treatment of solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - January 24, 2014 Category: Pharmaceuticals Source Type: news
Peregrine Pharmaceuticals begins Phase III lung cancer trial
US-based clinical stage biopharmaceutical company Peregrine Pharmaceuticals has started the patient enrolment in its SUNRISE trial, a pivotal Phase III study designed to evaluate the safety, tolerability and efficacy of bavituximab plus docetaxel in … (Source: Drug Development Technology)
Source: Drug Development Technology - January 2, 2014 Category: Pharmaceuticals Source Type: news
